엠마우스생명과학 게실증에 대한 엔다리 아웃 라이센싱 주도를 위하여 파트너 인터내셔널과 계약 체결
16 juil. 2020 19h00 HE
|
Emmaus Life Sciences
캘리포니아주 토랜스, July 17, 2020 (GLOBE NEWSWIRE) -- 겸상적혈구질환 치료의 선두주자인 Emmaus Life Sciences, 엠마우스생명과학, (“엠마우스”, OTCQB: EMMA)은 게실증 치료에 사용되는 엠마우스의 처방전 등급 L-글루타민 경구용 분말의 아웃 라이센싱 활동을 리드하기 위하여 파트너 인터내셔널과 계약을...
Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis
16 juil. 2020 08h00 HE
|
Emmaus Life Sciences
TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, is pleased to announce that it has engaged Partner...
Emmaus Life Sciences to Restate Previously Issued Financial Statements
08 juil. 2020 16h05 HE
|
Emmaus Life Sciences
TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued...
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of Health
29 juin 2020 08h00 HE
|
Emmaus Life Sciences
TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli...
미국국립의료원 (NIH), 엠마우스생명과학에 독점 특허 라이센스 부여
28 juin 2020 19h00 HE
|
Emmaus Life Sciences
캘리포니아주 토랜스, June 29, 2020 (GLOBE NEWSWIRE) -- 겸상적혈구질환 치료의 선두주자 엠마우스생명과학 (“엠마우스”, OTCQB: EMMA)은 2020년 06월 22일, 미국보건복지부, 국립보건원 산하, 국립암연구소에서 엠마우스생명과학의 자회사인 엠마우스메디컬에게 통지의 보충섹션에 나열된 특허출원 및 특허에서 구현된 발명을...
National Institutes of Health Announces Intention with Respect to Grant of Exclusive Patent License to Emmaus Life Sciences
25 juin 2020 08h00 HE
|
Emmaus Life Sciences
TORRANCE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that on June 22, 2020 the National institutes...
엠마우스생명과학 운영성과를 업데이트하여 공개
02 juin 2020 16h02 HE
|
Emmaus Life Sciences
캘리포니아주 토랜스, June 03, 2020 (GLOBE NEWSWIRE) -- 겸상적혈구질환 치료의 선두주자 엠마우스생명과학 (“엠마우스”, OTCQB: EMMA)은 2019년 12월 31일 연말결산 10-K 보고서 및 2020년 1분기 10-Q 보고서를 미국 증권거래위원회에 공시하기 전, 오늘 운영성과를 업데이트하여 공개했습니다. 최고경영자겸...
Emmaus Life Sciences Provides Operational Updates
02 juin 2020 08h00 HE
|
Emmaus Life Sciences
TORRANCE, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today operational updates in advance of the filing...
APCER Report Confirms Endari® Safety
27 avr. 2020 08h00 HE
|
Emmaus Life Sciences
TORRANCE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that APCER Life Sciences (APCER) has...
Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari® Priority Review Request
16 avr. 2020 08h00 HE
|
Emmaus Life Sciences
TORRANCE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the SFDA (Saudi Food & Drug...